Navigation Links
New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T
Date:11/7/2011

BRUSSELS and CHICAGO, Nov. 7, 2011 /PRNewswire/ -- UCB today announced new data which showed that treatment with Cimzia® (certolizumab pegol) was associated with a rapid and sustained clinical response over 28 weeks in a broad population of moderate to severe rheumatoid arthritis (RA) patients. The results, presented during the American College of Rheumatology's (ACR) 2011 Annual Scientific Meeting in Chicago, November 5-9, are from an open-label extension of the REALISTIC (RA EvALuation In Subjects receiving TNF Inhibitor Certolizumab pegol) study, and demonstrated consistent efficacy and improved physical function irrespective of prior anti-TNF therapy, concomitant disease modifying antirheumatic drugs (DMARDs), or duration of disease.

"These results are encouraging because they show that the rapid improvement in disease activity, as a result of the clinical response to certolizumab pegol, is sustained in patients who failed on previous therapies," said co-lead investigator Maxime Dougados, MD, Professor of Rheumatology, Rene Descartes University, Department of Rheumatology B, Cochin Hospital, Paris. "The data from the REALISTIC study is of interest because the trial included a broad RA patient population, which reflects aspects of the diversity we see day-to-day in clinical practice."*

Patients (n=1,063) who had participated in the 12-week randomized, double-blind, placebo-controlled REALISTIC study, either on certolizumab pegol or placebo plus DMARD, were given the option of participating in an open-label extension (OLE) study for a further 16 weeks (28 weeks in total). In total 954 patients entered the extension study and were given certolizumab pegol, including those patients that were previously treated with placebo in the 12-week controlled period of the trial. At Week 28, positive efficacy results were comparable between patients who had received certolizumab pegol for 28 weeks in total and those that switched from
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Vectorious Medical Technologies, an ... for patients suffering from congestive heart failure (CHF), ... million financing round. Investors in the round included ... Yehuda Zisapel and Prof. Nava Zisapel ; ... and others; and the U.S.-based Global Cardiovascular Innovation ...
(Date:2/26/2015)... 2015 Editor Note: For ... . Investor-Edge has initiated coverage on the ... ), Teva Pharmaceutical Industries Ltd (NYSE: TEVA ... Allergan Inc. (NYSE: AGN ), and Depomed ... on Johnson and Johnson can be accessed at ...
(Date:2/26/2015)... SALT LAKE CITY , Feb. 26, 2015 /PRNewswire/ ... it has launched a "best efforts" follow-on offering of ... unit consists of one share of Series E preferred ... Series E preferred stock will be convertible into four ... will be exercisable into one share of common stock ...
Breaking Medicine Technology:Vectorious Medical Technologies Completes $5M Raise 2Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 2Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 3Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 4Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 5Great Basin Scientific, Inc. Announces Commencement of Public Offering 2Great Basin Scientific, Inc. Announces Commencement of Public Offering 3
... , SAN DIEGO , Feb. 5 ... in the litigation filed by Lightlab Imaging, Inc. on January ... Suffolk County reached a verdict against Volcano and its ... acquired Axsun, which had an agreement to supply tunable lasers to ...
... Feb. 4 Mettler-Toledo International Inc. (NYSE: MTD ... highlights: , Sales in local currency declined by 5% in ... due to a 5% benefit from currency. , Net ... with $1.84 in the fourth quarter of 2008.  Adjusted EPS ...
Cached Medicine Technology:Volcano Corporation Announces Litigation Status 2Volcano Corporation Announces Litigation Status 3Mettler-Toledo International Inc. Reports Fourth Quarter 2009 Results 2Mettler-Toledo International Inc. Reports Fourth Quarter 2009 Results 3Mettler-Toledo International Inc. Reports Fourth Quarter 2009 Results 4Mettler-Toledo International Inc. Reports Fourth Quarter 2009 Results 5Mettler-Toledo International Inc. Reports Fourth Quarter 2009 Results 6Mettler-Toledo International Inc. Reports Fourth Quarter 2009 Results 7Mettler-Toledo International Inc. Reports Fourth Quarter 2009 Results 8Mettler-Toledo International Inc. Reports Fourth Quarter 2009 Results 9Mettler-Toledo International Inc. Reports Fourth Quarter 2009 Results 10Mettler-Toledo International Inc. Reports Fourth Quarter 2009 Results 11Mettler-Toledo International Inc. Reports Fourth Quarter 2009 Results 12Mettler-Toledo International Inc. Reports Fourth Quarter 2009 Results 13Mettler-Toledo International Inc. Reports Fourth Quarter 2009 Results 14Mettler-Toledo International Inc. Reports Fourth Quarter 2009 Results 15
(Date:2/26/2015)... Danvers, MA (PRWEB) February 27, 2015 ... of enterprise mobility management services, and one of ... announced they have engaged business development firm The ... CLEAN 4.0, Wireless Analytics’ latest iteration of the ... suite of services. The Endurance Group, based ...
(Date:2/26/2015)... Falls Church, VA (PRWEB) February 27, 2015 ... Edition, **FDAnews Publication**, http://www.fdanews.com/GuideToFDAMDRegs2015 , Whether a ... predicate device in a simple 510(k) filing or implement ... one thing all regulatory professionals need. The most up-to-date, ... why the Guide to FDA Medical Device Regulations is ...
(Date:2/26/2015)... (PRWEB) February 27, 2015 New ... is pleased to announce it is accepting new ... in Chesapeake, Va. , The new location ... physical therapy and rehabilitation programs, including the following ... and post orthopedic care, -Vestibular rehabilitation, -Neurological rehabilitation, ...
(Date:2/26/2015)... Dallas, Texas (PRWEB) February 27, 2015 ... Sodium Benzoate Industry is a professional and in-depth ... Sodium Benzoate industry with a focus ... in Sodium Benzoate market research are Wuhan Youji, ... Sonef, CG Chemikalien, MOLLER CHEMIE and W.ULRICH. , ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 In this ... professional runner Dr. Anne Shadle discusses her study that ... gold medal-winning athletes in Track and Field. Shadle wanted ... and technical training that impacted athletes’ success and helped ... she uncovered seem not only critical to peak athletic ...
Breaking Medicine News(10 mins):Health News:Wireless Analytics Engages The Endurance Group to Promote Upcoming CLEAN Platform™ 4.0 Launch 2Health News:Wireless Analytics Engages The Endurance Group to Promote Upcoming CLEAN Platform™ 4.0 Launch 3Health News:FDAnews Bestseller Updated: Guide to FDA Medical Device Regulations — 2015 Edition 2Health News:Tidewater Physical Therapy Accepting New Patients at Relocated Battlefield Clinic 2Health News:Global Sodium Benzoate Industry Analysis Report 2015-2020 Now at DeepResearchReports.com 2Health News:Global Sodium Benzoate Industry Analysis Report 2015-2020 Now at DeepResearchReports.com 3Health News:Anne Shadle and Controlling the Olympic Moment on SCI TV 2Health News:Anne Shadle and Controlling the Olympic Moment on SCI TV 3
... Organic chemistry textbooks will need to be revised to ... species - pentamethylcyclopentadienyl cation (a positively charged ion) - ... said it was unstable. // ,"I’ve said this ... in organic chemistry class, but, as it turns out, ...
... ingenuous technique which reshape the throat area helps people who ... operation, involving the co-ordinated action of various of the cranial ... at the upper end of the digestive tract// - that ... nerve is paralysed, aspiration of food down to the lungs, ...
... when a couple has sex and any subsequent risk of ... that the timing of sex might increase the risk of ... professor of obstetrics and gynecology at Baylor College of Medicine ... one of the known causes of birth defects in lower ...
... Queensland group have developed an efficient method of identifying ... of diseases such as meningococcal disease. The ... of Technology (QUT) has taken advantage of two new ... sequencing recently - DNA chip technology and comparative gene ...
... filtering out the antibodies that can cause donor kidney rejection ... patients need a kidney transplant but are denied one because ... bodies, are in short supply, and to have a kidney ... compatible blood group. ,But doctors at Johns Hopkins ...
... anti-ageing research, the liver is a neglected key. Professor ... felt that there are many wonderful things about getting ... mortgage is paid off, your children have moved out, ... have the benefit of wisdom and resilience," he said. ...
Cached Medicine News:Health News:Identifying bacteria made amiable 2Health News:Liver key to extending life 2
... ARUP Laboratories is a national reference ... development organization. ARUP offers an extensive ... unique medical tests in clinical and ... of Utah, ARUP Laboratories clients include ...
Disposable Microscissors: Horizontal Curved Microscissors...
Sharp tipped straight scissors. For cutting in the iris plane or cutting peripheral membranes. May also be useful in ROP cases....
Tapered Shaft Microscissors : Williams Curved SharpTipped Scissors...
Medicine Products: